An existing Alzheimer’s medication has been found to cut inflammation and insulin resistance in patients with metabolic syndrome, as per new clinical trial results put up by scientists at Northwell Health’s The Feinstein Institute for Medical Research.
Incyte reported that the first patient has been treated in a phase 3 trial dubbed GRAVITAS-301 for the first-line treatment of patients with acute graft-versus-host disease (GVHD).
Tiziana Life Sciences has started enrolling of patients in its phase IIa clinical trial with cyclin-dependent kinases (CDKs) inhibitor milciclib in patients with refractory hepatocellular carcinoma (HCC).
Vertex Pharmaceuticals has reported positive data from Phase 1 and Phase 2 trials of three different triple combination regimens in cystic fibrosis (CF) patients who have one F508del mutation and one minimal function mutation (F508del/Min).
PureTech Health has presented data for product candidate ALV-107 showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg), in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced Atlas Phase 3 clinical program for hemophilia treatment, fitusiran.
Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.
Prothena has reported that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early Parkinson's disease.
Zealand Pharma has started a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and the US).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.